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Pulmonary arterial hypertension (PAH) is a rare and devastating disease characterized by progressive increases in pulmonary arterial
pressure and pulmonary vascular resistance which eventually leads to
right ventricular failure and death. Early thought process was that exercise and increased physical activity may be detrimental to PAH patients
however many small cohort trials have proven otherwise. In addition to
the many pharmaceutical options, exercise and pulmonary rehabilitation have also been shown to increase exercise capacity as well as

various aspects of psychosomatic health. As pulmonary and exercise
rehabilitation become more widely used as an adjuvant therapy patient
outcomes improve and physicians should consider this in the therapeutic algorithm along with pharmacotherapy.
Keywords: Pulmonary arterial hypertension, Pulmonary rehabilitation,
Six minute walk test, Exercise intolerance, Pulmonary hypertension,
Health related quality of life

INTRODUCTION

cise and pulmonary rehabilitation have also been shown to increase exercise capacity, WHO functional class, peak oxygen consumption and resting heart rate (Grunig et al., 2011; 2012a). It
has also been seen that exercise may improve health related quality of life (HRQoL) (Chan et al., 2013), depression (Verma et al.,
2014) and fatigue (Talwar et al., 2014). It is imperative that clinicians use pulmonary rehabilitation and exercise as an adjuvant
therapy in the treatment of these patients as its benefits are clearly
evident. This review will attempt to emphasize the importance of
structured exercise training in the pulmonary hypertension population despite etiology and disease severity.

Pulmonary hypertension is a rare and devastating disease characterized by progressive increases in pulmonary arterial pressure
and pulmonary vascular resistance which eventually leads to right
ventricular failure and death (Badesch et al., 2009; Farber and Loscalzo, 2004). It may due to various etiologies such as left heart
disease, parenchymal lung disease, chronic thromboembolic disease, hematologic disorders or it may be idiopathic in nature (Table 1) (Simonneau et al., 2013) though the clinical picture of these
patients is similar. Patients with all forms of pulmonary hypertension present with progressive dyspnea and increasing exercise intolerance. More specifically WHO Group I pulmonary arterial
hypertension (PAH) is due to direct injury to the pulmonary vessels and vascular bed. At present there is no cure for PAH, however over the past decade targeted pharmaceutical options have become available. In addition to these pharmaceutical options, exer-

PULMONARY REHABILITATION
Over the last few decades pulmonary rehabilitation has advanced as a therapeutic option in patients of chronic respiratory
disease. Evidence based medicine has determined that pulmonary
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Table 1. World Health Organization's classification of pulmonary hypertension (Simonneau et al., 2013)
Group I - Pulmonary Arterial hypertension (PAH)
  Idiopathic PAH
   Heritable PAH (BMPR2, ALK1, ENG, SMAD9, CAV1, KCNK3, Unknown)
   Drug and toxin induced
   Associated with (i) Connective tissue disease, (ii) HIV infection, (iii) Portal hypertension, (iv) Congenital heart disease, (v) Schistosomiasis
   Pulmonary veno-occlusive disease and/ or pulmonary capillary hemangiomatosis
   Persistent pulmonary hypertension of the newborn
Group II - Pulmonary hypertension due to left heart disease
   Left ventricular systolic dysfunction
   Left ventricular diastolic dysfunction
  Valvular disease
   Congenital/ acquired left heart inflow/ outflow tract obstruction and congenital cardiomyopathies
Group III - Pulmonary hypertension due to lung diseases and/or hypoxia
   Chronic obstructive pulmonary disease
   Interstitial lung disease
   Other pulmonary diseases with mixed restrictive and obstructive pattern
  Sleep-disordered breathing
   Alveolar hypoventilation disorders
   Chronic exposure to high altitudes
   Developmental lung disease
Group IV - Chronic thromboembolic pulmonary hypertension (CTEPH)
Group V - Pulmonary hypertension with unclear multifactorial mechanisms
   Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
   Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleimyomatosis
   Metabolic disorders: glycogen storage disease, Gaucher’s disease, hypothyroidism
   Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension
5th World Symposium on Pulmonary Hypertension, Nice, France 2013. BMPR, Bone Morphogenic Protein Receptor Type II; CAV1, Caveolin-1; ENG, Endoglin; HIV, Human Immunodeficiency Virus.

rehabilitation can reduce dyspnea, increase exercise tolerance and
improve health related quality of life in all settings of chronic respiratory disease (Spruit et al., 2013). Pulmonary rehabilitation is
defined as a comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies, which include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to
promote the long-term adherence of health-enhancing behaviors
(Spruit et al., 2013).
Use of exercise training and pulmonary rehabilitation in cardiopulmonary diseases such as congestive heart failure (CHF) and
chronic obstructive pulmonary disease (COPD) have shown patient outcome improvement and are well described (Hambrecht
et al., 1998; Ries et al., 2007). However, in the setting of pulmonary hypertension only small cohorts of studies exist. The use of
exercise training and pulmonary rehabilitation in a pulmonary
hypertension population is still underutilized though studies have
shown its beneficial effect (de Man et al., 2009; Martinez-Quintana et al., 2010).

http://dx.doi.org/10.12965/jer.150190

PULMONARY ARTERIAL HYPERTENSION
AND EXERCISE IMPAIRMENT
Pulmonary arterial hypertension is characterized by a progressive increase in pulmonary vascular resistance, leading to right
ventricular failure and eventual death (Simonneau et al., 2013).
Prior to pharmacological intervention traditional therapies were
utilized which included anticoagulants, diuretics, and supplemental oxygen. However, after the pathophysiologic process became
well known disease-targeted therapies such as phosphodiesterase
inhibitors, endothelin receptor antagonists and prostacyclins have
become more widely used (Rubin, 2013). Combinations of these
agents are used to decrease pulmonary vascular resistance, decrease
pulmonary artery pressures and increase exercise tolerance (Pugh
et al., 2013). Combination therapy with disease specific drugs has
shown symptomatic relief as well as been shown to increase exercise capacity and possibly survival rate in pulmonary hypertension
(Ghofrani et al., 2002; Hoeper et al., 2004). Though these medications address quantitative measures of pulmonary vasculature
and hemodynamics, exercise capacity and quality of life continue
to decline despite optimized treatment.
http://www.e-jer.org
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Exercise capacity is reduced in the setting of pulmonary hypertension which is associated with depression and anxiety disorders
as demonstrated by Lowe et al. (2004). Until a better understanding of exercise training in the setting of pulmonary hypertension
was established the early thought process was that exercise and increased physical activity may be detrimental to these patients and
may actually increase pulmonary pressures expediting the proliferative process (Badesch et al., 2004).
The pathogenesis of pulmonary hypertension is multifactorial.
WHO group I pulmonary hypertension, also referred to as pulmonary arterial hypertension is characterized by abnormalities initiating in the small arteries of the pulmonary vasculature, including enhanced cell proliferation and reduced apoptosis, endothelial
dysfunction, thrombosis in situ, inflammation, and plexiform arteriopathy, leading to vascular remodeling and excessive vasoconstriction (McLaughlin et al., 2009). This may due to connective
tissue diseases, congenital heart disease, HIV infection, portal hypertension, heritable or it may be idiopathic in nature. In the setting of PAH these changes cause resistance for the blood flowing
through the pulmonary arteries. This leads to increased pulmonary artery pressures and increased pulmonary vascular resistance
pressures eventually leading to right heart failure due to increased
after load, decreased contractility, and reduced cardiac output
(Waxman, 2012). The combination of reduced cardiac output and
increased pulmonary vascular resistance creates a situation where
exertion causes dyspnea and negatively affects quality of life.
Exertional dyspnea being a common symptom across the pulmonary hypertension population provides a method to assess disease severity and progress. Dyspnea may be measures subjectively
by using instruments such as the Borg Dyspnea Scale and Medical
Research Council Dyspnea Scale (Bestall et al., 1999; Borg, 1970).
The severity of exertion is helpful to assess severity and prognosis
in pulmonary hypertension. The 6-min walk test and the measure
distance is used to assess exercise capacity in patients diagnosed
with pulmonary disease and is used as the determinant and primary endpoint in many exercise training clinical trials (ATS Committee on Proficiency Standards for Clinical Pulmonary Function
Laboratories, 2002). Exercise tolerance can also be measured using
cardiopulmonary exercise testing (American Thoracic, Society/
American College of Chest Physicians, 2003).

CLINICAL TRIALS OF EXERCISE TRAINING
AND PULMONARY REHABILITATION
Though early thought process advised against increased exer76
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tion and exercise a change in thinking brought upon clinical trials
of exercise respiratory training in the pulmonary hypertension
population (Table 2). In Mereles et al., (2006) conducted the first
prospective randomized study to evaluate the effects of exercise on
chronically ill pulmonary hypertension patients, stable on medication. Thirty patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension were
randomly assigned to either a control or training group. Primary
end points were the change in 6-min walk distance from baseline
to week 15 in the scores of the Short Form Health Survey quality-of-life questionnaire (SF-36). Secondary endpoints were also assessed. At week 15, patients in the primary and secondary training groups had an improved 6-min walking distance. Exercise
training was shown to be well tolerated and improved scores of
quality of life, WHO functional class and peak oxygen consumption. Systolic pulmonary artery pressure values at rest did not
change significantly after 15 weeks of exercise and respiratory
training (Mereles et al., 2006).
Though the ground work for exercise training in pulmonary hypertension was laid out, furthering testing was required. De Man et
al. (2009) conducted a trial of exercise on only patients with WHO
Group I PAH. Nineteen clinically stable PAH patients with moderate disease underwent exercise training program for 12 weeks in
which maximal capacity endurance capacity and quadriceps function were assessed and serial quadriceps muscle biopsies were obtained. 6-min walk distance and peak exercise capacity did not
change after training. However, endurance capacity improved significantly after training. Training also enhanced aerobic capacity of
the quadriceps, by increasing capillarization (de Man et al., 2009).
A study by Fox et al. (2011) of 22 PAH or CTEPH patients
demonstrated significant increase in 6 MWD as well as Peak VO2.
The rehabilitation program consisted of 24 1-h sessions of exercise
training/rehabilitation over the course of 12 weeks. Peak work rate
during cardiopulmonary exercise test also increased in the rehabilitation group with borderline significance. Echocardiography and
blood N-terminal pro-brain natriuretic peptide levels were unchanged. No adverse events occurred due to the rehabilitation program demonstrating safety.
With evidence of the positive benefits of exercise training in the
setting of pulmonary hypertension further clinical trials were conducted. Grunig et al. (2011) demonstrated the benefits of exercise
training in a connective tissue disease population with pulmonary
hypertension (Grunig et al., 2012b). Patients with RHC confirmed connective tissue disease related pulmonary hypertension
received in-hospital exercise training for 3 weeks which was conhttp://dx.doi.org/10.12965/jer.150190
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Table 2. Summary of exercise testing trial in the setting of pulmonary hypertension					
Study

n

Study Design

Intervention

Duration of Exercise/
Rehab Program

Mereles et al., 2006

30

RCT

Bicycle training, Walking, Dumbbell,
Respiratory Training

3 week in hospital+
12 weeks at home

De Man et al., 2009

19

Non-randomized
single group

Bicycle Training, Quadriceps stretch
and endurance

12 weeks in rehabilitation
center

Chan et al., 2013

23

RCT

Treadmill walking only for 30-45 min.

10 weeks 24-30 session in
rehabilitation facility

Fox et al., 2010

22

NRCT

12 weeks in outpatient
rehabilitation center

Grunig et al., 2011

58

NRCT single group

1 hr. per session, aerobic interval
training, bicycle, treadmill, walking,
step climbing; resistance training.
Daily bicycle training, dumbbell
training, respiratory training

Grunig et al., 2012

183 NRCT single group

3 weeks in hospital,
12 week at home

Grunig et al., 2012

21

Daily interval bicycle training, walking,
dumbbell training, mental training,
home
Daily interval bicycle training, walking,
dumbbell training, mental training,
home training

NRCT single group

3 weeks in hospital,
12 week at home

3 weeks in hospital,
12 week at home

Results
Improvement in 6MWD, QOL scores,
WHO FC, VO2 (peak +AT) and workload.
No change in SPAP; No SAE
Stable 6MWD, peak exercise capacity.
Increased muscle strength, capillaries in
muscle, oxidative enzyme activity.
Increase in 6MWD, QOL scores, Time to
exercise intolerance, Peak work rate; No
SAE
Increase in 6MWD, Peak VO2, Peak WR.
BNP, SPAP and CO remained the same;
No SAE
Increased 6MWD, QOL scores, WHO FC,
Peak VO2, Maximum workload and
decreased resting HR; No SAE
Increased 6MWD, QOL scores, WHO FC,
Peak VO2; Decreased resting heart rate, and
SPAP; No SAE
Increased 6MWD, QOL scores, WHO FC,
Peak VO2, Maximum workload increased O2
SPAP; Survival at 2 yr-100%, 3 yr 73%

RCT, Randomized Controlled Trial; 6MWD, 6-min walk distance; QOL, Quality of life; WHO-FC, World Health Organization Functional Class; SAE, Serious Adverse Events; NRCT,
Non-Randomized Control Trial; HR, Heart Rate; BNP, Brain Natruietric Peptide; SPAP, Systolic Pulmonary Artery Pressure.				

tinued for another 12 weeks at home. Patients improved the mean
distance walked in 6 min, resting heart rate, peak oxygen consumption, and oxygen saturation. In addition systolic pulmonary
artery pressure, and diastolic systemic blood pressure improved
significantly after 3 weeks of exercise training. The 1- and 2-yr
overall-survival rates were found to be 100%, the 3-yr survival rate
73% (Grunig et al., 2012a).
Another study by Grunig et al. (2011) aimed to assess disease
progression and survival in patients with severe chronic pulmonary hypertension. Fifty eight patients with severe pulmonary hypertension on stable medication received exercise and respiratory
training in hospital for 3 weeks which was later continued at
home. They were prospectively followed for 24 ± 12 months. Primary endpoints were time to clinical worsening and survival. Adverse events and changes in the 6-min walking test, QoL, WHO
functional class and gas exchange were secondary endpoints and
were evaluated at baseline and at weeks 3 and 15. The results
showed that all patients tolerated the exercise training well without any severe adverse events. In week 15, 6-min walking test results were significantly improved compared to baseline as well as
quality of life scores, WHO functional class, peak oxygen consumption, heart rate at rest and maximal workload. Survival at 1
and 2 yr was 100 and 95%, respectively (Grunig et al., 2011).
http://dx.doi.org/10.12965/jer.150190

Fifteen events occurred during the follow-up. It was concluded
that exercise and respiratory training as add-on to medical treatment may improve exercise capacity and QoL, with a good long
term safety profile.

NON PHYSICAL EFFECTS OF EXERCISE
AND PULMONARY REHABILITATION
As pulmonary hypertension’s most debilitating manifestation is
exercise intolerance most trials focus on improvement in this characteristic as well as hemodynamics. However, in addition to physical improvement, there is a great deal of improvement in aspects of
psychosomatic domains. It is well known that patients with pulmonary hypertension experience depression (Verma et al., 2014)
and report increased levels of fatigue severity (Talwar et al., 2014).
It is also well known that these patients have a severely impaired
health related quality of life (Taichman et al., 2005). These aspects
of psychosomatic medicine may also be addressed with the use of
structured pulmonary rehabilitation and exercise programs in this
population. A study by Kim et al. (2013) showed the effects that
dyspnea has on depression and health related quality of life
(HRQoL). Pulmonary rehabilitation programs have also showed
improvement in fatigue severity as well as depression (Talwar et al.,
http://www.e-jer.org
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2014) which provide evidence of further benefits of such programs.
A more recent study by Chan et al. (2013) went ahead to determine the effects of intense treadmill exercise on cardio-respiratory
function as well as quality of life in patients with pulmonary hypertension. Patients were randomized to a 10-week disease specific education only group or education/exercise combined group.
The exercise program consisted of 24-30 sessions of treadmill
walking for 30-45 min per session. Outcome variables included
changes in 6-min walk test (6 MWT) distance, time to exercise
intolerance, peak work rate from a cardiopulmonary treadmill
test, and quality-of-life measures, including the SF-36 and Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
(Chan et al., 2013). The results following 10 weeks of intervention, demonstrated an improvement in 6 MWT distance, increased time to exercise intolerance, and peak WR. Additionally,
the exercise group showed increased quality of life score according
to the SF-36 as well as the CAMPHOR scale (Chan et al., 2013).

ported.

CONCLUSIONS

Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Use-

REFERENCES
American Thoracic Society/American College of Chest P. ATS/ACCP
Statement on cardiopulmonary exercise testing. Am J Respir Crit Care
Med 2003;167(2):211-277.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk
test. Am J Respir Crit Care Med 2002;166(1):111-117.
Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau
G, McLaughlin VV; American College of Chest Physicians. Medical
therapy for pulmonary arterial hypertension: ACCP evidence-based
clinical practice guidelines. Chest 2004;126(1 Suppl):35S-62S.
Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes
A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll
Cardiol 2009;54(1 Suppl):S55-S66.
fulness of the Medical Research Council (MRC) dyspnoea scale as a

Pharmacotherapy for pulmonary arterial hypertension has advanced over the past decade and has provided clinicians with a
disease specific approach which has led to the improvement in
prognosis of PAH patients. However, patients continue to experience significant exertional symptoms accompanied by reduced
functional capacity and diminished health-related quality of life.
From the trials that have been conducted, the evidence supports
the benefits and safety of exercise training and rehabilitation programs in the pulmonary hypertension populations. Initial exercise
training and pulmonary rehabilitation programs were assessed in
a stable, treated, systolic heart failure, and COPD and showed improved functional capacity and reduced exercise intolerance,
symptoms of dyspnea, and fatigue.
Trials conducted in a pulmonary hypertension population
showed improvement in exercise endurance and muscle strength
as well as quality of life with the implementation of exercise training and cardiopulmonary rehabilitation as part of their medical
care without a good safety profile. In conjunction with pharmacotherapy all patients with confirmed pulmonary arterial hypertension should be treated with a pulmonary rehabilitation and exercise training program.

measure of disability in patients with chronic obstructive pulmonary
disease. Thorax 1999;54(7):581-586.
Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2(2):92-98.
Chan L, Chin LM, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA, Connors G, Weir NA, Drinkard B, Lamberti J, Keyser RE.
Benefits of intensive treadmill exercise training on cardiorespiratory
function and quality of life in patients with pulmonary hypertension.
Chest 2013;143(2):333-343.
de Man FS, Handoko ML, Groepenhoff H, van ‘t Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, Postmus
PE, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Effects of
exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34(3):669-675.
Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med
2004;351(16):1655-1665.
Fox BD, Kassirer M, Weiss I, Raviv Y, Peled N, Shitrit D, Kramer MR.
Ambulatory rehabilitation improves exercise capacity in patients with
pulmonary hypertension. J Card Fail 2011;17(3):196-200.
Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT,
Weissmann N, Seeger W, Grimminger F. Combination therapy with
oral sildenafil and inhaled iloprost for severe pulmonary hyperten-

CONFLICT OF INTEREST

sion. Ann Intern Med 2002;136(7):515-522.
Grunig E, Ehlken N, Ghofrani A, Staehler G, Meyer FJ, Juenger J, Opitz

No potential conflict of interest relevant to this article was re78

http://www.e-jer.org

CF, Klose H, Wilkens H, Rosenkranz S, Olschewski H, Halank M. Ef-

http://dx.doi.org/10.12965/jer.150190

Sahni S, et al. • Pulmonary rehabilitation in pulmonary arterial hypertension

fect of exercise and respiratory training on clinical progression and

Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M,

survival in patients with severe chronic pulmonary hypertension.

Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J,

Respiration 2011;81(5):394-401.

Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Exercise

Grunig E, Lichtblau M, Ehlken N, Ghofrani HA, Reichenberger F, Stae-

and respiratory training improve exercise capacity and quality of life

hler G, Halank M, Fischer C, Seyfarth HJ, Klose H, Meyer A, Sorichter

in patients with severe chronic pulmonary hypertension. Circulation

S, Wilkens H, Rosenkranz S, Opitz C, Leuchte H, Karger G, Speich R,
Nagel C. Safety and efficacy of exercise training in various forms of
pulmonary hypertension. Eur Respir J 2012a;40(1):84-92.

2006;114(14):1482-1489.
Pugh ME, Hemnes AR, Robbins IM. Combination therapy in pulmonary
arterial hypertension. Clin Chest Med 2013;34(4):841-855.

Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, , Fiehn C,

Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA,

Stöckl F, Prange F, Staehler G, Reichenberger F, Tiede H, Halank M,

Make B, Rochester CL, Zuwallack R, Herrerias C. Pulmonary Rehabil-

Seyfarth HJ, Wagner S, Nagel C. Exercise training in pulmonary arte-

itation: Joint ACCP/AACVPR Evidence-Based Clinical Practice

rial hypertension associated with connective tissue diseases. Arthritis
Res Ther 2012b;14(3):R148.
Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Ad-

Guidelines. Chest 2007;131(5 Suppl):4S-42S.
Rubin LJ. Pulmonary hypertension: current management and future directions. Handb Exp Pharmacol 2013;218:551-555.

ams V, Niebauer J, Schuler G. Regular physical exercise corrects endo-

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani

thelial dysfunction and improves exercise capacity in patients with

A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado

chronic heart failure. Circulation 1998;98(24):2709-2715.

RF, Olschewski H, Robbins IM, Souza R. Updated clinical classifica-

Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J.
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24(6):1007-1010.

tion of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-41.
Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K,

Kim EJ, Verma S, Sahni S, Athanasiou K, Patel P, Kohn N, Talwar A. Dys-

Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bour-

pnea, depression and health related quality of life [HRQoL] in pa-

beau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I,

tients with pulmonary arterial hypertension [PAH]. Chest 2013;144(4

Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troost-

Meeting Abstracts):864A-A.

ers T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF,

Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, Borst MM.

Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo

Anxiety and depression in patients with pulmonary hypertension.

R, Meek P, Morgan M, Rutten-van Mölken MP, Ries AL, Make B,

Psychosom Med 2004;66(6):831-836.

Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF; ATS/

Martinez-Quintana E, Miranda-Calderin G, Ugarte-Lopetegui A, Rodri-

ERS Task Force on Pulmonary Rehabilitation. An official American

guez-Gonzalez F. Rehabilitation program in adult congenital heart

Thoracic Society/European Respiratory Society statement: key con-

disease patients with pulmonary hypertension. Congenit Heart Dis

cepts and advances in pulmonary rehabilitation. Am J Respir Crit

2010;5(1):44-50.

Care Med 2013;188(8):e13-64.

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner

Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, Gallop

JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ,

R, Christie J, Hansen-Flaschen J, Palevsky H. Health-related quality of

Tapson VF, Varga J; American College of Cardiology Foundation Task

life in patients with pulmonary arterial hypertension. Respir Res

Force on Expert Consensus Documents; American Heart Association;

2005;6:92.

American College of Chest Physicians; American Thoracic Society,

Talwar A, Sahni S, John S, Verma S, Cardenas-Garcia J, Kohn N. Effects of

Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert

pulmonary rehabilitation on Fatigue Severity Scale in patients with

consensus document on pulmonary hypertension a report of the

lung disease. Pneumonol Alergol Pol 2014;82(6):534-540.

American College of Cardiology Foundation Task Force on Expert

Verma S, Cardenas-Garcia J, Mohapatra PR, Talwar A. Depression in pul-

Consensus Documents and the American Heart Association devel-

monary arterial hypertension and interstitial lung diseases. N Am J

oped in collaboration with the American College of Chest Physicians;

Med Sci 2014;6(6):240-249.

American Thoracic Society, Inc.; and the Pulmonary Hypertension
Association. J Am Coll Cardiol 2009;53(17):1573-1619.

http://dx.doi.org/10.12965/jer.150190

Waxman AB. Exercise physiology and pulmonary arterial hypertension.
Prog Cardiovasc Dis 2012;55(2):172-179.

http://www.e-jer.org

79

